Cipla launches generic Idiopathic Pulmonary Fibrosis drug Nintedanib in India
New Delhi: Pharma major Cipla on Tuesday said it has launched generic Nintedanib used for the treatment of Idiopathic Pulmonary Fibrosis (IPF) under the brand name 'Nintib' in India.
Available as 100 mg and 150 mg capsules, the launch marks another milestone in the company's decade-long commitment to treat IPF, a rare lung disease that impacts ten in one lakh people, Cipla said in a statement.
In line with its endeavour of enabling effective and affordable management of IPF, Nintib is priced at Rs 69 (100 mg) and Rs 85 (150 mg) per capsule, it added.
IPF is a chronic progressive form of lung disease with an average survival rate of three to five years if left untreated. It is characterised by scarring in the lungs, wherein the lung tissue becomes stiff and thick, Cipla said.
Read also: Cipla gets USFDA nod for Dimethyl Fumarate DR Capsules to treat multiple sclerosis
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.